Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control AAT Clear all
Completed Phase 4 Interventional Results available

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

NCT00261833
View directory record Official record
Conditions
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Interventions
Alpha1-proteinase inhibitor, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 18, 2026, 8:22 AM EDT
Terminated Not applicable Interventional Results available

Neural and Behavioral Effects of Cognitive Bias Modification (CBM)

NCT04430543
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Cognitive Bias Modification, Sham Training
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 34 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health

NCT00571844
View directory record Official record
Conditions
Hypertension
Interventions
DASH diet, DASH diet plus Weight loss
Behavioral
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

NCT01812447
View directory record Official record
Conditions
Emphysema
Interventions
Spiration Valve System, Medical Management
Device · Other
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
32
States / cities
Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen

NCT02496637
View directory record Official record
Conditions
Obesity, Eating Disorders
Interventions
Appetite Awareness, Nutrition Education
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 20 Years · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional

The Neurobiology of Approach Avoidance Training in Depression

NCT02330744
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Approach-positive AAT, Control AAT
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

NCT01684410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional

mHealth Behavior Study

NCT06624514
View directory record Official record
Conditions
Alcohol Consumption, Condom Use
Interventions
Training Group, Sham Training Group
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

NCT04762771
View directory record Official record
Conditions
Covid19
Interventions
Colchicine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 18, 2026, 8:22 AM EDT
Completed No phase listed Observational

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

NCT01810458
View directory record Official record
Conditions
Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
Interventions
Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Phase 3 Interventional Results available

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

NCT04167514
View directory record Official record
Conditions
Graft Versus Host Disease (GVHD)
Interventions
Alpha-1 antitrypsin (AAT), Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Recruiting Phase 3 Interventional

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran Injection, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 18, 2026, 8:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Reducing Binge Eating to Prevent Weight Gain in Black Women

NCT03531112
View directory record Official record
Conditions
Binge Eating, Weight Loss, Weight Gain Prevention
Interventions
Appetite Awareness Treatment + Lifestyle Modification
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 18, 2026, 8:22 AM EDT
Recruiting Not applicable Interventional

Animal Assisted Therapy After Pediatric Brain Injury: Mediators and Moderators of Treatment Response.

NCT05250180
View directory record Official record
Conditions
Brain Injuries
Interventions
Animal Assisted Therapy, Control
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

NCT05569759
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
zetomipzomib, placebo, zetomipzomib in open-label extension
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions
Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior

NCT05426460
View directory record Official record
Conditions
Smoking Behaviors, Smoking, Cigarette
Interventions
Approach/Avoidance Task, Transcranial Direct Current Stimulation, AC, Sham tDCS
Behavioral · Device
Lead sponsor
Cynthia Conklin
Other
Eligibility
26 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 18, 2026, 8:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

NCT01851642
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
Interventions
History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2033
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 18, 2026, 8:22 AM EDT
Terminated Phase 2Phase 3 Interventional

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

NCT03805789
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
AAT, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AAT Training in Smokers

NCT02481752
View directory record Official record
Conditions
Tobacco Use
Interventions
Approach Avoidance Training, SHAM Training
Other
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 8:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency

NCT02691611
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 18, 2026, 8:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
GLASSIA, methylprednisolone or equivalent steroid, Albumin
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 18, 2026, 8:22 AM EDT
Terminated Phase 3 Interventional Results available

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

NCT02722304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions
ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 18, 2026, 8:22 AM EDT